Search results
Results from the WOW.Com Content Network
In a Cochrane systematic review the dose-related magnitude of atorvastatin on blood lipids was determined. Over the dose range of 10 to 80 mg/day total cholesterol was reduced by 27.0% to 37.9%, LDL cholesterol by 37.1% to 51.7% and triglycerides by 18.0% to 28.3%. [99]
Guidelines by the American College of Cardiology and the American Heart Association recommend statin treatment for primary prevention of cardiovascular disease in adults with LDL cholesterol ≥ 190 mg/dL (4.9 mmol/L) or those with diabetes, age 40–75 with LDL-C 70–190 mg/dL (1.8–4.9 mmol/dL); or in those with a 10-year risk of developing ...
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
Jb Reed, Bloomberg via Getty Images By Emily Jane Fox CVS (CVS) charges $150 for a monthly prescription of the generic version of the cholesterol drug Lipitor. The same drug goes for $17 at Costco.
Ezetimibe is a medication used to treat high blood cholesterol and certain other lipid abnormalities. [3][4] Generally it is used together with dietary changes and a statin. [5] Alone, it is less preferred than a statin. [4] It is taken by mouth. [4] It is also available in the fixed combinations ezetimibe/simvastatin, [6] ezetimibe ...
Psychosis risk increases 81% on high-dose amphetamine. For this study, researchers analyzed medical data from adults between the ages of 16 and 35 treated at Mass General Brigham between 2005 and ...
High doses of commonly prescribed medications for ADHD have been linked to an increased risk of ... Patients taking 20 mg to 40 mg of Adderall, 50 mg to 100 mg of Vyvanse or 15 mg to 30 mg of ...
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.